[go: up one dir, main page]

MX2018008558A - Anticuerpos monoclonales anti-cd47 humanizados, de raton, o quimericos. - Google Patents

Anticuerpos monoclonales anti-cd47 humanizados, de raton, o quimericos.

Info

Publication number
MX2018008558A
MX2018008558A MX2018008558A MX2018008558A MX2018008558A MX 2018008558 A MX2018008558 A MX 2018008558A MX 2018008558 A MX2018008558 A MX 2018008558A MX 2018008558 A MX2018008558 A MX 2018008558A MX 2018008558 A MX2018008558 A MX 2018008558A
Authority
MX
Mexico
Prior art keywords
monoclonal antibodies
humanized
chimeric anti
antibodies
mouse
Prior art date
Application number
MX2018008558A
Other languages
English (en)
Inventor
Chlons- Cottavoz Marie
Lahmar Mehdi
Schwamborn Klaus
Beltraminelli Nicola
Fallot Stéphanie
Garrone Pierre
Original Assignee
Forty Seven Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forty Seven Inc filed Critical Forty Seven Inc
Publication of MX2018008558A publication Critical patent/MX2018008558A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a anticuerpos monoclonales anti-CD47 humanizados, de ratón o quiméricos. Los anticuerpos se unen a CD47 glicosilado y desglicosilado humano con un valor Kdisoc optimizado, interrumpen la interacción de SIRPa-CD47 humano, y encuentran uso en varios métodos terapéuticos, preventivos o de diagnóstico. La invención incluye anticuerpos aislados y derivados y fragmentos de los mismos, formulaciones farmacéuticas que comprenden uno o más de los anticuerpos monoclonales anti-CD47 humanizados o quiméricos; y líneas celulares que producen estos anticuerpos monoclonales. También se proporcionan secuencias de aminoácido y nucleótido de los anticuerpos.
MX2018008558A 2016-01-11 2017-01-11 Anticuerpos monoclonales anti-cd47 humanizados, de raton, o quimericos. MX2018008558A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16150808 2016-01-11
EP16172651 2016-06-02
PCT/EP2017/050508 WO2017121771A1 (en) 2016-01-11 2017-01-11 Humanized, mouse or chimeric anti-cd47 monoclonal antibodies

Publications (1)

Publication Number Publication Date
MX2018008558A true MX2018008558A (es) 2019-05-06

Family

ID=57860833

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018008558A MX2018008558A (es) 2016-01-11 2017-01-11 Anticuerpos monoclonales anti-cd47 humanizados, de raton, o quimericos.
MX2023000781A MX2023000781A (es) 2016-01-11 2018-07-11 Anticuerpos monoclonales anti-cd47 humanizados, de raton, o quimericos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023000781A MX2023000781A (es) 2016-01-11 2018-07-11 Anticuerpos monoclonales anti-cd47 humanizados, de raton, o quimericos.

Country Status (19)

Country Link
US (3) US10927173B2 (es)
EP (2) EP3402820B1 (es)
JP (2) JP7099957B2 (es)
KR (2) KR20220163516A (es)
CN (2) CN114716552B (es)
AU (2) AU2017206631B2 (es)
CA (2) CA3177526A1 (es)
DK (1) DK3402820T3 (es)
EA (1) EA038880B1 (es)
ES (1) ES2796378T3 (es)
HR (1) HRP20201085T1 (es)
IL (2) IL290425B2 (es)
MX (2) MX2018008558A (es)
PL (1) PL3402820T3 (es)
PT (1) PT3402820T (es)
SG (1) SG11201805894YA (es)
SI (1) SI3402820T1 (es)
WO (1) WO2017121771A1 (es)
ZA (1) ZA201805337B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10927173B2 (en) 2016-01-11 2021-02-23 Forty Seven, Inc. Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
EP3411071A4 (en) 2016-10-20 2019-08-28 I-Mab NOVEL MONOCLONAL CD47 ANTIBODY AND USES THEREOF
CN111448210B (zh) 2017-07-26 2024-05-14 四十七公司 抗SIRP-α抗体及相关方法
WO2019020807A1 (en) 2017-07-28 2019-01-31 Gene Signal International Sa CD9P-1 TARGETING ANTIBODIES AND USES THEREOF
BR112020001679A2 (pt) * 2017-08-02 2020-07-21 Phanes Therapeutics, Inc. anticorpos anti-cd47 e usos dos mesmos
EP3668897B1 (en) 2017-08-18 2024-06-05 Centessa Pharmaceuticals (UK) Limited Binding agents
PL4177270T3 (pl) * 2017-10-18 2024-11-18 Forty Seven, Inc. Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47
AU2018358004A1 (en) * 2017-11-01 2020-05-28 Hummingbird Bioscience Pte. Ltd. CD47 antigen-binding molecules
EA202091339A1 (ru) * 2017-12-01 2020-10-21 Сиэтл Дженетикс, Инк. Антитела против cd47 и их применение для лечения онкологических заболеваний
CN111699005A (zh) 2018-02-12 2020-09-22 四十七公司 使用抗cd47抗体和抗cd20抗体的抗癌方案
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
GB201804860D0 (en) * 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
KR20210029158A (ko) 2018-06-03 2021-03-15 람카프 바이오 베타 엘티디. Ceacam5 및 cd47에 대한 이중특이성 항체
CN110577597B (zh) * 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
EP3817769A4 (en) * 2018-07-05 2022-03-30 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
EA202092684A1 (ru) 2018-08-27 2021-03-11 Ридженерон Фармасьютикалз, Инк. Применение рамановской спектроскопии для последующей очистки
JP7583707B2 (ja) * 2018-08-31 2024-11-14 南京聖和薬業股▲ふん▼有限公司 抗ｃｄ４７抗体及びその応用
MX2021004779A (es) * 2018-10-31 2021-06-08 I Mab Biopharma Us Ltd Anticuerpos cd47 novedosos y metodos para usarlos.
TW202104260A (zh) 2019-04-05 2021-02-01 美商西建公司 腫瘤選擇性結合ｃｄ４７之抗體之工程
EP3955963A4 (en) * 2019-04-18 2023-05-31 QLSF Biotherapeutics Inc. ANTIBODIES TARGETING HUMAN CD47
EP3980747A1 (en) 2019-06-07 2022-04-13 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
JP2022545974A (ja) * 2019-09-03 2022-11-01 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｄ４７モノクローナル抗体及びその使用
PH12022550835A1 (en) 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
WO2021078219A1 (en) * 2019-10-25 2021-04-29 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-cd47 antibodies and uses thereof
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
CN115397853A (zh) 2019-12-17 2022-11-25 辉瑞大药厂 对cd47、pd-l1具特异性的抗体及其用途
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
MX2022009947A (es) 2020-02-14 2022-11-07 Jounce Therapeutics Inc Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
EP4127139A1 (en) 2020-03-27 2023-02-08 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CN113939533B (zh) * 2020-06-18 2022-12-06 武汉全景生物技术有限公司 抗可溶性cd14亚型抗体、试剂盒及其应用
KR20230033647A (ko) 2020-06-30 2023-03-08 멘두스 비.브이. 난소암 백신에서 백혈병 유래 세포의 용도
CN112010979B (zh) * 2020-08-21 2022-05-10 博奥信生物技术（南京）有限公司 一种抗人SIRPα单克隆抗体及其用途
AU2021346729A1 (en) * 2020-09-28 2023-05-11 Shanghai Henlius Biologics Co., Ltd. Anti-cd47 antibodies and methods of use
JP2023552375A (ja) 2020-12-06 2023-12-15 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体
KR102757518B1 (ko) * 2020-12-07 2025-01-21 (주)이노베이션바이오 Cd47에 특이적인 항체 및 이의 용도
US20230312709A1 (en) * 2020-12-23 2023-10-05 Guangdong Feipeng Pharmaceutical Co., Ltd. Antibody targeting CD47 and application thereof
WO2022148412A1 (zh) * 2021-01-08 2022-07-14 北京韩美药品有限公司 特异性结合cd47的抗体及其抗原结合片段
JP2024510989A (ja) 2021-03-12 2024-03-12 メンドゥス・ベスローテン・フェンノートシャップ ワクチン接種方法及びｃｄ４７遮断薬の使用
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023277281A1 (ko) * 2021-06-30 2023-01-05 (주)이노베이션바이오 Cd47에 특이적인 인간화 항체 및 이를 포함하는 cd47 관련 질환의 예방 또는 치료용 약학적 조성물
JP2024539252A (ja) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
CN116136491A (zh) * 2021-11-18 2023-05-19 中山康方生物医药有限公司 检测抗cd47抗体的装置和检测方法
EP4452415A1 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
IT202100033002A1 (it) * 2021-12-29 2023-06-29 Diatheva S R L Anticorpi umani e loro usi
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
HUE069263T2 (hu) 2022-03-17 2025-02-28 Gilead Sciences Inc Ikarosz cink-ujj család degradálói és azok alkalmazása
JP2025509662A (ja) 2022-03-24 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
EP4499711A1 (en) * 2022-03-25 2025-02-05 WuXi Biologics Ireland Limited Anti-her2/anti-cd47 molecules and uses thereof
WO2023191117A1 (ko) * 2022-03-28 2023-10-05 (주)이노베이션바이오 친화도가 성숙된 cd47에 특이적인 인간화 항체
WO2023186067A1 (en) * 2022-03-31 2023-10-05 I-Mab Biopharma Co., Ltd. Combination therapies comprising an anti-her2 antibody-drug conjugate for the treatment of cancer
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
CN117257935A (zh) * 2022-06-21 2023-12-22 广东菲鹏制药股份有限公司 一种含抗cd47抗体或其抗原结合片段的制剂及其制备方法和应用
PE20250758A1 (es) 2022-07-01 2025-03-13 Gilead Sciences Inc Compuestos de cd73
EP4554628A1 (en) 2022-07-12 2025-05-21 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
KR20250122479A (ko) 2022-12-22 2025-08-13 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN118909129B (zh) * 2024-07-31 2025-04-01 上海吉至生化科技有限公司 抗大鼠IgG的抗体、抗体组合物和试剂盒

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
CA2226962A1 (en) 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
GB9930706D0 (en) * 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
JP2005526501A (ja) 2002-02-21 2005-09-08 デューク・ユニヴァーシティ 自己免疫疾患用の試薬および治療方法
US20050180972A1 (en) 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
JP4637749B2 (ja) 2003-11-11 2011-02-23 中外製薬株式会社 ヒト化抗ｃｄ４７抗体
US7601355B2 (en) 2005-06-01 2009-10-13 Northwestern University Compositions and methods for altering immune function
US20090191202A1 (en) 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP2139922A1 (en) 2007-03-28 2010-01-06 Biogen Idec, Inc. Treatment of hodgkins lymphoma
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
JP4453724B2 (ja) 2007-06-29 2010-04-21 株式会社デンソー 車両用冷凍サイクル装置
JP4148367B1 (ja) 2007-08-02 2008-09-10 富山県 細胞のスクリーニング方法
EP2207797A4 (en) * 2007-10-11 2010-12-22 Univ Health Network MODULATION OF THE SIRPALPHA CD47 INTERACTION TO IMPROVE TRANSPLANTATION OF HUMAN HEMATOPOETIC STEM CELLS AND COMPOUNDS THEREOF
ES2796085T3 (es) 2008-01-15 2020-11-25 Univ Leland Stanford Junior Marcadores de células madre de leucemia mieloide aguda
JP5547656B2 (ja) 2008-01-15 2014-07-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７によって媒介される食作用を操作するための方法
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
SI2477648T1 (sl) 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Sinergijska terapija proti CD47 za krvne rake
ES2609043T3 (es) 2009-11-30 2017-04-18 Janssen Biotech, Inc. Anticuerpos mutantes Fc con funciones de efecto abladas
CA3138956A1 (en) 2010-05-14 2011-11-17 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
US20140242095A1 (en) 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
AU2013209736C1 (en) 2012-01-17 2017-12-14 The Board Of Trustees Of The Leland Stanford Junior University High affinity SIRP-alpha reagents
MY169341A (en) 2012-02-06 2019-03-21 Inhibrx Inc Cd47 antibodies and methods of use thereof
PT2925782T (pt) * 2012-12-03 2020-04-22 Novimmune Sa Anticorpos anti-cd47 e métodos de utilização destes
BR112015013431A2 (pt) 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
US9969789B2 (en) 2012-12-17 2018-05-15 Trillium Therapeutics Inc. Treatment of CD47+ disease cells with SIRP alpha-Fc fusions
EP2953643B1 (en) * 2013-02-06 2023-02-22 Inhibrx, Inc. Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
CN103665165B (zh) * 2013-08-28 2016-02-24 江苏匡亚生物医药科技有限公司 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途
JP6606505B2 (ja) 2014-03-11 2019-11-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体
TWI702228B (zh) 2014-08-08 2020-08-21 美商Ａｌｘ腫瘤技術股份有限公司 信號調節蛋白α（ｓｉｇｎａｌ-ｒｅｇｕｌａｔｏｒｙ ｐｒｏｔｅｉｎ α， ＳＩＲＰ-α）變體構築物及其用途
CN104804093A (zh) * 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
SG10202101909RA (en) 2015-08-07 2021-04-29 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
EP4186927B1 (en) 2015-10-21 2025-04-23 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
WO2017100462A2 (en) 2015-12-11 2017-06-15 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with dual targeting of cd47 and egfr
US10927173B2 (en) 2016-01-11 2021-02-23 Forty Seven, Inc. Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
KR102833922B1 (ko) 2016-01-21 2025-07-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 면역조절제의 조합물에 의한 암의 치료
CN109195634A (zh) 2016-04-15 2019-01-11 延龄草疗法有限公司 Cd47阻断治疗中的巨噬细胞刺激
CN111448210B (zh) 2017-07-26 2024-05-14 四十七公司 抗SIRP-α抗体及相关方法
CA3078430A1 (en) 2017-10-18 2019-04-25 Forty Seven, Inc. Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
PL4177270T3 (pl) 2017-10-18 2024-11-18 Forty Seven, Inc. Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47
CN111699005A (zh) 2018-02-12 2020-09-22 四十七公司 使用抗cd47抗体和抗cd20抗体的抗癌方案

Also Published As

Publication number Publication date
JP7375122B2 (ja) 2023-11-07
SI3402820T1 (sl) 2021-04-30
IL290425B2 (en) 2024-02-01
BR112018014028A2 (pt) 2019-02-05
PL3402820T3 (pl) 2020-11-16
CA3011097A1 (en) 2017-07-20
CA3011097C (en) 2022-12-20
MX2023000781A (es) 2023-02-14
ZA201805337B (en) 2020-11-25
PT3402820T (pt) 2020-08-20
JP2022174033A (ja) 2022-11-22
AU2021202966B2 (en) 2024-03-21
EP3402820A1 (en) 2018-11-21
DK3402820T3 (da) 2020-05-18
KR102472087B1 (ko) 2022-11-29
US10927173B2 (en) 2021-02-23
CA3177526A1 (en) 2017-07-20
US12060423B2 (en) 2024-08-13
CN108495863A (zh) 2018-09-04
CN114716552A (zh) 2022-07-08
ES2796378T3 (es) 2020-11-26
CN108495863B (zh) 2022-05-03
US11643461B2 (en) 2023-05-09
EA201891435A1 (ru) 2018-12-28
JP2019508030A (ja) 2019-03-28
WO2017121771A1 (en) 2017-07-20
AU2017206631A8 (en) 2018-08-23
CN114716552B (zh) 2024-05-24
US20190023784A1 (en) 2019-01-24
US20210188976A1 (en) 2021-06-24
NZ784152A (en) 2025-02-28
KR20220163516A (ko) 2022-12-09
NZ744264A (en) 2024-08-30
SG11201805894YA (en) 2018-08-30
US20220356245A1 (en) 2022-11-10
IL290425A (en) 2022-04-01
AU2017206631B2 (en) 2021-02-11
AU2021202966A1 (en) 2021-06-03
EP3747906A1 (en) 2020-12-09
JP7099957B2 (ja) 2022-07-12
AU2017206631A1 (en) 2018-08-02
IL290425B1 (en) 2023-10-01
IL260542B (en) 2022-03-01
KR20180095086A (ko) 2018-08-24
EP3402820B1 (en) 2020-05-06
EA038880B1 (ru) 2021-11-01
HRP20201085T1 (hr) 2020-10-30

Similar Documents

Publication Publication Date Title
MX2023000781A (es) Anticuerpos monoclonales anti-cd47 humanizados, de raton, o quimericos.
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
WO2011143624A3 (en) Humanized and chimeric monoclonal antibodies to cd47
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
HK1254861A1 (zh) 抗lag3抗体及其用途
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
ZA201708265B (en) Tigit-binding agents and uses thereof
EP4275698A3 (en) Anti-tigit antibodies and methods of use thereof
WO2018170338A3 (en) High affinity mage-a1-specific tcrs and uses thereof
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
EP4289484A3 (en) Anti-ctla-4 antibodies and methods of use thereof
WO2018089508A3 (en) Anti-cd47 antibodies
HK1258509A1 (zh) Gitr激动剂
WO2015161267A3 (en) Humanized and chimeric monoclonal antibodies to cd99
WO2016100985A3 (en) Chimeric antigen receptors and methods of use thereof
HK1250990A1 (zh) 凝血因子xi抗体及使用方法
WO2016014565A3 (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
EP4269563A3 (en) Anti-gd2 antibodies
WO2016063026A3 (en) Selective nav protein binders
EP4183806A3 (en) Glycan-interacting compounds and methods of use
WO2018031490A3 (en) Anti-ox40 binding proteins
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
WO2018069871A3 (en) Anti-kras binding proteins
MX2019011624A (es) Metodos y composiciones para la reduccion de la inmunogenicidad.